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Abstract
Overview: Cardiovascular disease remains a leading cause of death worldwide, with vulnerable plaque rupture the
underlying cause of many heart attacks and strokes. Much research is focused on identifying an imaging biomarker to
differentiate stable and vulnerable plaque. Magnetic Resonance Imaging (MRI) is a non-ionising and non-invasive
imaging modality with excellent soft tissue contrast. However, MRI has relatively low sensitivity (micromolar) for
contrast agent detection compared to nuclear imaging techniques. There is also an increasing emphasis on developing
MRI probes that are not based on gadolinium chelates because of increasing concerns over associated systemic
toxicity and deposits1. To address the sensitivity and safety concerns of gadolinium this project focused on the
development of a high relaxivity probe based on superparamagnetic iron oxide nanoparticles for the imaging of
atherosclerotic plaque with MRI. With development, this may facilitate differentiating stable and vulnerable plaque in
vivo.
Aim: To develop a range of MRI contrast agents based on superparamagnetic iron oxide nanoparticles (SPIONs), and
test them in a murine model of advanced atherosclerosis.
Methods: Nanoparticles of four core sizes were synthesised by thermal decomposition and coated with
poly(maleicanhydride-alt-1-octadecene) (PMAO), poly(ethyleneimine) (PEI) or alendronate, then characterised for
core size, hydrodynamic size, surface potential and relaxivity. On the basis of these results, one candidate was
selected for further studies. In vivo studies using 10 nm PMAO-coated SPIONs were performed in ApoE-/- mice fed a
western diet and instrumented with a perivascular cuff on the left carotid artery. Control ApoE-/- mice were fed a
normal chow diet and were not instrumented. Mice were scanned on a 3T MR scanner (Philips Achieva) with the
novel SPION contrast agent, and an elastin-targeted gadolinium agent that was shown previously to enable
visualisation of plaque burden. Histological analysis was undertaken to confirm imaging findings through staining for
macrophages, CX3CL1, elastin, tropoelastin, and iron.
Results: The lead SPION agent consisted of a 10 nm iron oxide core with poly(maleicanhydride-alt-1-octadecene),
(-36.21 mV, r2 18.806 mmol-1/s-1). The irregular faceting of the iron oxide core resulted in high relaxivity and the
PMAO provided a foundation for further functionalisation on surface -COOH groups. The properties of the contrast
agent, including the negative surface charge and hydrodynamic size, were designed to maximise circulation time and
evade rapid clearance through the renal system or phagocytosis. In vitro testing showed that the SPION agent was
non-toxic.
In vivo results show that the novel contrast agent accumulates in similar vascular regions to a gadolinium-based
contrast agent (Gd-ESMA) targeted to elastin, which accumulates in plaque. There was a significant difference in
SPION signal between the instrumented and the contralateral non-instrumented vessels in diseased mice (p = 0.0411,
student’s t-test), and between the instrumented diseased vessel and control vessels (p = 0.0043, 0.0022, student’s
t-test). There was no significant difference between the uptake of either contrast agent between stable and vulnerable
plaques (p = 0.3225, student’s t-test). Histological verification was used to identify plaques, and Berlin Blue staining
confirmed the presence of nanoparticle deposits within vulnerable plaques and co-localisation with macrophages.
Conclusion: This work presents a new MRI contrast agent for atherosclerosis which uses an under-explored surface
ligand, demonstrating promising properties for in vivo behaviour, is still in circulation 24 hours post-injection with
limited liver uptake, and shows good accumulation in a murine plaque model.
Key words: MRI contrast agents, vulnerable plaque, atherosclerosis, superparamagnetic iron oxide nanoparticles
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Introduction
Cardiovascular disease (CVD), including
myocardial infarction and stroke, remains a leading
cause of death and long-term disability worldwide
[2], costing the UK in excess of €26 billion per year to
treat [3]. The high mortality is mainly caused by
coronary atherosclerosis and the high morbidity by
carotid atherosclerosis and associated stroke.
Atherosclerosis is a chronic, inflammatory, lipiddriven disease of the artery walls. Atherosclerotic
plaques are classified in a variety of ways and here we
adopt the simple difference between vulnerable and
stable plaques, which is based on their propensity to
rupture with ensuing thrombosis that might occlude
the lumen.
A major challenge for medical imaging is the
development of a contrast agent which can
differentiate between vulnerable and stable plaques,
to identify rupture-prone lesions and perhaps to
enable treatment to trigger plaque stabilisation or
regression and prevent subsequent cardiovascular
events. This is particularly important given the
asymptomatic nature of vulnerable plaque, and the
low survival rates for out-of-hospital cardiac arrests
(as measured by patients subsequently discharged
alive from hospital) remaining below 10% [3].
The
current
gold-standard for human
atherosclerosis imaging is Optical Coherence
Tomography (OCT) which can differentiate between
plaque phenotypes, but which is an invasive
technique. Computer tomography has also shown
great promise in vulnerable plaque detection but
exposes patients to inonizing radiation and thus is not
ideal for repeat exams [4].
Magnetic Resonance Imaging (MRI) is a
non-invasive imaging technique with excellent
resolution which does not use ionising radiation to
generate excellent soft tissue contrast. To further
enhance contrast between normal and diseased
tissues, or to obtain molecular and cellular
information, MR contrast agents can be used. By far
the majority of MRI contrast agents are based on
gadolinium-chelates which generate positive T1
contrast
through
paramagnetism.
However,
increasingly, alternatives to gadolinium are being
sought due to toxicity concerns particularly in
patients with kidney disease, and recent studies
which have found gadolinium deposits in patients’
brains [1,5,6].
Commercial, off-the-shelf, non-targeted SPIONs
have been previously used to image atherosclerotic
plaques in patients [7,8]. Whilst these studies indicate
that SPIONs successfully image atherosclerotic
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plaques, the exact correlation with plaque phenotype
is less clear.
The aim of this study was to develop a range of
MRI contrast agents based on superparamagnetic iron
oxide nanoparticles (SPIONs) with different surface
functionalisation, and test them in a murine model of
advanced atherosclerosis to determine whether a
long-circulating, non-toxic SPION contrast agent
might offer an alternative to invasive intravascular
OCT or ultrasound, and to more traditional
gadolinium-containing MRI contrast agents for the
detection of vulnerable plaque.

Results and Discussion
Contrast agent development
SPIONs were synthesised using the thermal
decomposition method first reported by Sun et. al. [9].
Four different size cores (6, 8, 10, 12 nm) were grown
to examine the relationship between core size and
relaxivity. The hydrophobic particles were phase
transferred using three different ligand systems, poly
(maleic anhydride-alt-1-octadecene) (PMAO) [10],
alendronate [11], and poly(ethyleneimine) (PEI). The
surface ligands all offered different characteristics,
comparing encapsulation (PMAO), and ligand
exchange (alendronate and PEI), different surface
groups (-COOH and -NH2), as well as newer (PMAO)
and more established ligands (PEI).
The nanoparticles were characterised in terms of
core size, hydrodynamic size, surface charge, and
relaxivity. Hydrodynamic size and surface charge are
both important considerations in predicting and
governing in vivo behaviour. Long circulation times
allow the contrast agent to accumulate in plaque
through a combination of phagocytosis by plaque
macrophages, and the enhanced permeability and
retention (EPR) effect arising from endothelial
dysfunction. This would also provide a platform for
potential targeting of the probe to vulnerable
plaque-specific proteins such as CX3CL1 [12-16],
VCAM-1 [17-19], VEGF [20], or αvβ3 integrin [21]
through antibodies, which require long-circulation to
be effective targeting moieties. In addition to an
imaging platform, targeting the probe to chemokines
such as CX3CL1, CCR2 or CCL5 would have potential
therapeutic benefits. These chemokines are all
associated with vulnerable plaque, and blocking their
expression has been shown to lead to plaque
stabilisation and regression [15,22]. Developing a
long-circulating probe targeted to one or multiple of
these proteins would aid in the detection of
vulnerable plaque, as well as treating it in situ and
improving patient outcomes.

http://www.ntno.org
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In order to ensure the long circulation of the
probe, the clearance route was of primary
consideration. There is a size window between 6-200
nm for avoiding renal clearance (<6 nm) [23] and
clearance
immediately
through
the
reticuloendothelial system (>200 nm). Core size was
measured by transmission electron microscopy (TEM)
(Figure 1) and hydrodynamic size through dynamic
light scattering (DLS) (Table 1). Surface charge
particularly affects interaction with the immune
system, where neutral agents are longer-circulating,
positively-charged agents clear faster due to higher
intracellular uptake resulting from the electrostatic
attraction to the cell membrane, and opsonisation by
proteins in the blood stream accelerating phagocytosis
[24-26]. Negatively-charged agents are not as
long-circulating as neutral agents but are better than
positively-charged agents for antibody targeting.
DLS and visual inspection both showed the
formation of large aggregates with both amine-based
surface ligands, and PEI in particular, was very
challenging to exchange onto the nanoparticles
despite testing multiple conditions. PMAO showed
much narrower size dispersions and improved
stability, in water and phosphate buffered saline in
accordance with literature findings [27]. The
carboxylic acid groups on the surface of the PMAOcoated particles resulted in a negative surface charge,
and that in combination with the narrower size
dispersion, lack of aggregation and long-term stability
made it the most suitable choice for this contrast
agent. PMAO has also not seen application in vivo yet,
and the probe is therefore novel in surface
functionalisation, and looks to be a promising
platform for many applications. Nanoparticle contrast
agents are easily tuned to many different targets and
applications, and -COOH groups are easily
functionalised with targeting moieties for molecular
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imaging, dyes or fluorophores for optical imaging and
potentially histology, chelators for radionuclides or
gadolinium, meaning that this probe has potential
across a wide spectrum of applications and
modalities.
The relaxivity measurements were the decisive
factor in selecting the lead-candidate for antibodycoupling, with the 10 nm nanoparticle cores showing
the highest r2 (18.806 mmol-1s-1). An anti-CX3CL1
antibody was coupled to the surface of the probe
through carbodiimide coupling to test the feasibility
of molecular targeting, and tests indicated that the
antibody was successfully coupled to the nanoparticle
surface, and that it retained binding ability after
coupling.

In vitro evaluation
A cell viability assay using RAW 264.7 murine
macrophages was undertaken to confirm the contrast
agent was non-toxic. Cells were incubated with
varying concentrations of iron in excess of what might
be encountered in vivo, and the SPIONs were
compared to FeCl3. Cell viability was assessed using a
standard tetrazolium/formazan cell viability dye
[2,3-bis-(2-methoxy,
4-nitro,
5-(sulfophenyl)-2Htetrazolium-5-carboxanilide) (XTT)] measured with
absorbance spectroscopy, by minor modification of
previous methods [28-32]. Higher measured cell
survival was observed for those cells treated with
SPIONs as opposed to FeCl3 at all concentrations, as
can be observed in Figure 2. For each concentration,
cell survival was higher for SPIONs than the
corresponding amount of FeCl3, further evidence that
the SPIONs were at least as well tolerated as
unencapsulated Fe. For reference, Fe is measurable in
peripheral serum at a peak concentration of
approximately 10 mM after a conventional dietary
iron supplement [33] (Figure 2).

Figure 1. TEM characterisation. (A) Graph showing measured nanoparticle core size versus projected nanoparticle core size. (B) TEM image showing irregular
faceting of nanoparticle cores.
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Figure 2. Cell survival assays with SPIONS. Graphs demonstrating measured cell survival of RAW 264.7 murine macrophages at 24 hours incubation with
varying concentrations of iron in the form of anti-Fractalkine SPIONs or FeCl3. (A) Cell counts using a hemacytometer at 24 hours showing an equivalent and slight
loss of cells at 24 hours at extreme concentrations (100 µM) of SPIONs and FeCl3. (B) Colorimetric cell survival assay based on formazan (XTT) reduction, also
carried out at 24 hours and also showing an equivalent slight loss of cells at 24 hours at extreme concentrations (100 µM) of SPIONs, whether targeted or untargeted
(no antibody). FeCl3 increases apparent cell number, although that is likely to represent an artefact e.g. mitochondrial dysfunction. Data were also obtained at 2 hours,
when there was very little effect (not shown).

Table 1. Hydrodynamic size and surface potential measurements
for all synthesised nanoparticles
Sample
6 nm iron oxide with PEI
8 nm iron oxide with PEI
10 nm iron oxide with PEI
12 nm iron oxide with PEI
6 nm iron oxide with PMAO
8 nm iron oxide with PMAO
10 nm iron oxide with PMAO
12 nm iron oxide with PMAO
6 nm iron oxide with alendronate
8 nm iron oxide with alendronate
10 nm iron oxide with alendronate
12 nm iron oxide with alendronate

Diameter in nm
148.5
206.5
--371.5
113.2
104.7
194.6
139.6
199.5
292.7
194.0
266.4

Potential in mV
3.30
1.60
10.91
5.73
-42.11
-36.66
-36.21
-22.84
26.86
12.12
26.60
28.44

non-targeted SPIONs were incubated against murine
CX3CL1 or control-coatings on 96-well plates (see
Methods). To obtain an unambiguous demonstration
that iron-containing particles were captured by plateadsorbed fractalkine, unbound particles were
removed through a gentle wash and plate-bound iron
detected a reaction product with Berlin Blue (acidified
potassium ferricyanide, a classical reagent for
detecting immobilized iron) added. After 10-20 mins
incubation, Berlin Blue/iron complex was measured
by UV-Vis. spectroscopy. The results (Figure 3)
demonstrated higher levels of bound iron detected in
the wells with targeted SPIONs as opposed to control
SPIONs.

In vivo evaluation

Figure 3. Specific binding of anti-factalkine SPIONs to immobilised
fractalkine shown by Berlin-Blue based iron measurement. Graph
showing bound as detected by Berlin Blue and UV-Vis. spectroscopy in wells
coated with CX3CL1 and incubated with targeted and non-targeted SPIONs.
*p<0.05, ANOVA.

In order to confirm that the anti-fractalkineSPION conjugate specifically targeted fractalkine, a
binding assay was designed. Both targeted and

The contrast agent was tested in a murine model
of advanced (vulnerable) plaque: 6 ApoE-/- C57/Bl6
female mice fed a high fat diet with a cuff placed on
the left carotid artery for 9 weeks to cause a stenosis
and changes in wall shear stress patterns. The model
was developed to cause a vulnerable plaque upstream
of the cuff and a stable plaque downstream of the cuff,
which made it particularly suitable for testing this
contrast agent by enabling the direct comparison of
uptake in known vulnerable and stable plaque sites
[34].
The mice were first injected with a
gadolinium-containing elastin-specific MR contrast
agent (Gd-ESMA) which has been characterised in
atherosclerosis models, allowed to visualise the
location and extend of plaque and provided a
benchmark for the novel contrast agent. The mice
were then injected with the SPIONs and imaged 24
hours post-injection. The results are illustrated in
Figures 4 and 5.
http://www.ntno.org
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Figure 4. Top to bottom, (A) Left: graph showing lumen area versus slice number, demonstrating a consistent decrease in lumen area from slice 3-5 (standardised
relative to aortic arch) in all 6 animals (represented by different legends) corresponding to cuff location; right: anatomical scan showing the location of the cuff and
resulting arterial stenosis; (B) Left: Magnetic Resonance Angiography scan (Top) showing the brachiocephalic artery, left carotid artery, and left subclavian artery
(L-R), Bottom: Inversion recovery image showing plaque areas with Late Gadolinium enhancement from Gd-ESMA in the vessel walls. Right: Image overlay showing
the areas of enhancement in relation to the vessel lumen. (C) Two examples of T2* echo scans based on the protocol from Makowski et. al. [35] showing negative
contrast areas in the vessel walls.

The Gd-ESMA scans showed a significant
difference between uptake in the cuffed vessel
compared with the contralateral control vessel (p =
0.018), demonstrating that the cuff placement and
hyperlipidemia led to the formation of plaque more
rapidly than hyperlipidemia alone through alterations
of wall shear stress. There was also a significant
difference between the Gd-ESMA signal in the cuffed
disease vessel compared to both the left and right
carotid arteries in the control animals ((p = 0.002,
0.000095), supporting the plaque formation as a result
of hyperlipidemia and placement of the cuff with
resultant stenosis (Figure 5). The data was analysed
using multiple non-parametric t-tests corrected for

multiple comparisons by the Holm-Sidak method,
and was found to be statistically significant. There
was no notable difference in Gd-ESMA signal
between the stable and vulnerable plaque regions
measured in three slices above and below the stenosis
of the cuff, but it was not expected that elastin content
would differ significantly, particularly given that
Gd-ESMA binds to both the cross-linked mature form
of elastin, and its precursor tropoelastin. Interestingly,
the brachiocephalic artery was observed to be
enlarged related to other murine atherosclerosis
models, and this is likely to be a result of
compensation due to the restriction the cuff places on
the left carotid.
http://www.ntno.org
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Figure 5. (A) Graph showing plaque volume as measured by area of late-gadolinium enhancement in both the left (LCA) and right (RCA) carotid arteries of control
(left) and diseased (right) animals, showing that cuff placement and hyperlipidemia increase plaque size in the instrumented diseased left carotid artery (*p<0.05,
student’s t-test); (B) graph showing plaque volume as measured by T2* enhancement in the left (LCA) and right (RCA) carotid arteries of control (left) and diseased
(right) animals, showing that cuff placement hyperlipidemia increase plaque size in the instrumented diseased left carotid artery (*p<0.05, student’s t-test); (C) graph
showing area of void (AOV) arising from SPIONs and area of late-gadolinium enhancement (AOE) arising from Gd-ESMA in control regions pre- (upstream) and
post-cuff (downstream), although differences are present, no level of significance was reached.

The SPION behavior mirrored Gd-ESMA signal,
validating the novel contrast agent against an
established agent to measure plaque burden. Again,
there was a significant difference between the
modified vessel and the internal control vessel (p =
0.018), and between the modified, diseased vessel and
both vessels in the control animalsp = 0.005, 0.002)
(Figure 5). The data was analysed using multiple nonparametric t-tests corrected for multiple comparisons
by the Holm-Sidak method, and was found to be
statistically significant.
There was no significant difference between the
uptake of either contrast agent between the
vulnerable plaque upstream of the cuff, and the stable
plaque downstream of the cuff (p = 0.32, student’s
t-test) (Figure 5).

Histological verification
Imaged plaques and control sections of artery
were then analysed through histology and
immunohistochemistry, staining sections for elastin,
tropoelastin, CD68, CX3CL1 (a marker for vulnerable
plaque), and iron. Berlin blue staining for iron
confirmed the presence of SPION-derived iron in the
plaques of diseased vessels (Figure 8), but there was

no Berlin blue staining in the control vessels. There
was a significant difference in expression of both
CD68 which is a macrophage marker, and Fractalkine
between sections of tissue from diseased and healthy
control animals. Levels of tropoelastin were also
elevated in plaque regions. These findings are
illustrated in Figures 6 and 7.

Conclusions
In conclusion, this paper illustrates the
development of a novel superparamagnetic iron oxide
nanoparticle contrast agent which successfully
allowed imaging of atherosclerotic plaques with MRI.
Although the probe is not specific for vulnerable
plaque, it is non-toxic and accumulates in similar
regions to an elastin-targeted agent for visualizing
plaque burden. It also provides a good platform for
further refinement towards a vulnerable plaquespecific contrast agent in the future. The novel probe
has successfully been labelled with an antibody, and
the conjugated antibody has been demonstrated to
retain binding specificity for the target. There is a
limitation in that the nanoparticles were labelled with
an anti-CX3CL1 antibody, however this labelling was
at a low proportion of the injected dose and so the
http://www.ntno.org
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probe has not been treated as a targeted agent.
Because of this, no conclusions can be drawn
regarding potential levels of CX3CL1 expression in
the plaques, although previous work by Cheng et. al.
suggests that CX3CL1 is elevated in vulnerable
plaques [11].

Methods
Chemistry
Synthesis of 6 nm hydrophobic SPIONs [36]
Fe(acac)3 (0.71 g, 2 mmol) and 1,2-hexadecanediol (2.58 g, 10 mmol) were dissolved in benzyl
ether (20 ml). Oleic acid (2.11 ml, 6 mmol) and
oleylamine (2.80 ml, 6 mmol) were added, and the
mixture was stirred for 2 hours under N2 at 200 °C.
The mixture was then heated to reflux (300 °C) for 1
hour and cooled by the removal of the heat source.
Nanoparticles were precipitated with EtOH (40
ml) and centrifuged for 30 minutes at 4000 rpm. Pellet
was re-dispersed in hexane (20 ml), centrifuged for 10
minutes at 4000 rpm and then precipitated again with
EtOH (20 ml). The solution was centrifuged for 30

190
minutes at 4000 rpm, supernatant removed and pellet
dried under vacuum. SPIONs were stored dry.

Seed-mediated growth of SPIONs [36]
Fe(acac)3
(0.18
g,
0.5
mmol)
and
1,2-hexadecanediol (0.65 g, 2.5 mmol) were dissolved
in benzyl ether (15 ml). Oleic acid (0.70 ml, 0.5 mmol),
oleylamine (0.93 ml, 0.5 mmol) and SPIONs (5-10 mg)
were added and the mixture was stirred for 1 hour at
200 °C. The mixture was then heated to reflux (300 °C)
for half an hour and cooled by the removal of the heat
source.
The workup was performed as with 6 nm
hydrophobic SPIONs.

Coating with poly(maleic anhydride-alt-1-octadecene)
[10]
Poly(maleic
anhydride-alt-1-octadecene)
(PMAO) (45 mg) was dissolved in CHCl3 (20 ml). The
SPIONs (2 mg) were added and mixture was stirred
for 30 minutes. Chloroform was removed, and residue
re-dissolved in a small amount of CHCl3. NaOH (aq)
(0.05 M) was added and mixture was heated at 60 °C
until SPIONs transferred to the aqueous phase.

Figure 6. From top to bottom and left to right: (A) Graph illustrating the percentage vessel wall area of CX3CL1 measured in diseased and control sections; (B)
Graph illustrating the percentage vessel wall area of CD68 measured in diseased and control sections; (C) Graph illustrating the plaque area measured in diseased and
control sections; (D) Graph illustrating the percentage vessel wall area of tropoelastin measured in diseased and control sections.
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Figure 7. (A) Section of control vessel stained for elastin and, (B) section of diseased vessel stained for elastin showing a plaque. (C-D) Sections of diseased vessel
stained for tropoelastin, showing a plaque. (E) Section of diseased vessel showing a plaque stained for CD68, and (F) section of diseased vessel showing a plaque
stained for CX3CL1.

The solution was filtered using on a 0.45 µm
filter, and then concentrated by centrifugation with a
filter of 30k Mw. Particles were re-suspended in water
and stored.

Coating with alendronate [11]
Sodium alendronate trihydrate (50 mg) was

dissolved in water (5 ml) adjusted to pH 9 with 1 M
KOH. The SPIONs (6 mg) were suspended in THF.
The solutions were combined and stirred at room
temperature for 2 days. The solution was magnetically
decanted and washed with acetone (3 × 10 ml). The
particles were re-suspended in water and stored.
http://www.ntno.org
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Figure 8. Examples of sections stained for iron with Berlin Blue, highlighting the
blue deposits in plaque regions.
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carried out under PPL 70/8482 at King’s College
London.
Homozygous female ApoE-/- mice (C57BL/6J
background) were acquired from Charles Rivers
Laboratories (Edinburgh, UK) and bred within the
Behavioural Sciences Unit of the Rayne Institute. The
housing and care of the animals, and all procedures in
this study were performed in accordance with the
guidelines and regulations of the UK home office.
At 11 weeks of age the mice were placed on high
fat diet (HFD) (21% fat, 0.25% cholesterol wt/wt from
LBS-Biotech) for two weeks prior to surgery. Two
weeks after commencement of HFD the mice
underwent surgery for the placement of a rigid
polyether ketone perivascular cuff (Promolding, The
Netherlands) around the left carotid. The cuff was
supplied in two pieces and when assembled the
lumen narrowed from 500 µm to 250 µm over 1.5 mm.
The animals were kept under anaesthesia at 1.5-2.5%
isoflurane and 2% O2, with anaesthetic depth being
assessed from respiratory rate, hind limb muscle tone,
and pedal withdrawal reflex as previously described
[34].
The animals then remained on HFD for a further
9 weeks before scanning and sacrifice. Animals were
euthanised under Schedule 1 with an overdose of
anaesthetic followed by exsanguination and flushing
of the vasculature with saline.
Healthy ApoE-/- mice with no cuff fed a normal
chow diet were used as controls.

Imaging Studies: Gd-ESMA
Biology
In vitro cell toxicity assay
Preparation of XTT working reagent:
5 ml of PBS (Phosphate Buffered Saline) and 50
µl of XTT (25 mg/ml) and 0.5 µl PMS (Phenazine
methosulfate, 50 mg/ml) was added into a clean 15 ml
conical centrifuge tube.
In a 96 well plate each well was seeded with 200
µl of 10k RAW 264.7 cells in IMDM with 10% FBS. The
plate was incubated overnight, and then treated with
SPIONs at different concentrations: 0 µM, 1 µM, 10
µM and 100 µM. The plate was incubated overnight,
and 20 µl of XTT reagent as prepared above was
added to the wells and incubated. The absorbance
was measured at 2 and 24 hours post-addition of XTT
at 450 and 540 nm.

Animal Model
All animal experiments complied with the
Animals (Scientific Procedures) Act 1986 and were

Based on previous studies carried out by
Makowski et. al. [37] animals were injected with 0.2
mmol/kg Gd-ESMA in 150 µl sterile saline through
the tail vein. The animals were then scanned 1 hour
post-injection.
In vivo vessel wall imaging was performed using
a Philips Achieva MR scanner (Philips Healthcare,
Best, The Netherlands) equipped with a clinical
gradient system (30 mT m−1, 200 mT m−1 ms−1).
The brachiocephalic artery (BCA) and left and
right carotids were imaged using a single-loop surface
coil (diameter = 23 mm). Mice were placed in prone
position after intravenous administration of 0.2
mmol/kg Gd-ESMA (Lantheus Medical Imaging,
North Billerica, MA). Anesthesia was induced with
5% and maintained with 1% to 2% isoflurane during
the MRI experiments.
After a 3-dimensional gradient recalled echo
scout scan, contrast-enhanced angiography images
were acquired with a field of view (FOV) = 30× 30× 8
mm, matrix = 200× 200, in-plane resolution = 0.15×
0.15× 0.5 mm (reconstructed = 0.10× 0.10 mm),
repetition time/echo time = 15/6.1 ms, and flip angle
http://www.ntno.org

Nanotheranostics 2020, Vol. 4
= 40°. The maximum intensity projection images were
used to plan the subsequent delayed-enhancement
(DE) and T1 mapping scans. A 2-dimensional
Look-Locker sequence was acquired using the
following parameters: FOV = 30× 30 mm, matrix =
80× 80, in-plane resolution = 0.38× 0.38× 2 mm,
repetition time/echo time = 19/8.6 ms, repetition time
between subsequent inversion recovery pulses = 1000
ms, and flip angle = 10°. An inversion recovery
3-dimensional fast gradient echo sequence was
acquired with FOV = 30× 30× 8 mm, matrix = 304×
304, in-plane resolution = 0.1× 0.1× 0.5 mm, repetition
time/echo time = 28/8 ms, repetition time between
subsequent inversion recovery pulses = 1000 ms, and
flip angle = 30°. T1 mapping was performed with the
same sequence employed for the aorta. The
acquisition parameters were as follows: FOV = 36×
22× 8 mm, matrix = 192× 102, in-plane resolution =
0.18× 0.22× 0.5 mm, slices = 16, repetition time/echo
time = 9.6/4.9 ms, flip angle = 10°.

Imaging Studies: SPIONs
Animals were injected with 150 µl 6 mM [Fe]
SPIONs in sterile saline through the tail vein. The
animals were then scanned 24 hours post-injection.
The imaging protocols were based on previous
experiments by Makowski et. al. [35] and were carried
out on a Phillips 3T Achieva scanner (Philips
Healthcare, Best, The Netherlands) equipped with a
clinical gradient system (30 mT m−1, 200 mT m−1 ms−1)
as before.
The brachiocephalic artery (BCA) and left and
right carotids were imaged using a single-loop surface
coil (diameter=23 mm). Mice were placed in prone
position. Anesthesia was induced with 5% and
maintained with 1% to 2% isoflurane during the MRI
experiments.
After a 3-dimensional gradient recalled echo
scout scan, contrast-enhanced angiography images
were acquired with a field of view (FOV) = 30× 30× 8
mm, matrix = 200× 200, in-plane resolution = 0.15×
0.15× 0.5 mm (reconstructed = 0.10× 0.10 mm),
repetition time/echo time = 15/6.1 ms, and flip angle
= 40°. The maximum intensity projection images were
used to plan the subsequent T2*-weighted 3D gradient
echo scan. ECG-triggering was not used, and a
T2*-weighted 3D gradient echo data set was acquired
with FOV = 16× 16× 8; matrix = 176× 176; in-plane
spatial resolution = 0.12× 0.12 mm; slice thickness =
0.5 mm; TR/TE = 37.88/7.32 ms and flip angle = 25°.

Histology
Elastin Staining
Deparaffinised slides were incubated in working
elastic stain solution for 10 minutes and rinsed in
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deionized water. Slides were then placed in ferric
chloride solution for 22 seconds, rinsed under running
water and checked under the microscope. Slides were
rinsed in 96% ethanol to remove excess iodine, then
rinsed in deionized water. Slides were incubated in
van Gieson solution for 1-3 minutes. Finally, slides
were dehydrated through a gradient of ethanol,
cleared in xylene, and mounted.

Prussian Blue Staining
20% aqueous solution of hydrochloric acid (20
ml conc. HCl, 80 ml water) and 10% potassium
ferrocyanide trihydrate (10 g, 100 ml water) were
prepared and mixed fresh before staining. Slides were
immersed in the solution for 20 minutes then washed
in deionized water three times before counterstaining
with nuclear fast red for 5 minutes. Finally, slides
were dehydrated through a gradient of ethanol,
cleared in xylene, and mounted.

Immunohistochemistry
Deparaffinised slides were stained for tropoelastin, CD68
or CX3CL1 using the following protocol:
Endogenous peroxidase was inhibited by
incubation of the slides in 3% oxygenated water and
methanol for 10 minutes. Slides were then washed in
deionized water for 10 minutes. Antigen retrieval was
performed by boiling the samples for 2 minutes at 110
°C in citrate buffer in a pressurized antigen retrieval
unit and then allowed to cool. Samples were washed
with PBS for 3 minutes, and blocking was performed
for 1 hour at room temperature with 10% donkey
serum in PBS. Incubation with the primary antibody
was carried out overnight at 4 ˚C diluted 1:100 in PBS
2% normal donkey serum. Samples were allowed to
temper at room temperature for 1 hour, then slides
were washed twice in PBS for 20 minutes. Slides were
incubated with anti-rabbit HRP polymer for 45
minutes at room temperature then washed 3 times in
PBS for 5 minutes.
Slides were revealed with Vector SG Peroxidase
substrate for 10 minutes at room temperature
PBS (5 ml), Chromogen (75 μl), Hydrogen peroxide
(120 μl).
Samples were washed twice in PBS for 5
minutes, before counterstaining with nuclear fast red
for 5 minutes. Slides were washed with deionized
water then finally dehydrated through a gradient of
ethanol, cleared in xylene, and mounted.

Supplementary Material
Supplementary figure S1.
http://www.ntno.org/v04p0184s1.pdf
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